Atrial fibrillation (AF) is the most common sustained arrhythmia seen in clinical practice, affecting approximately 1% of the overall population. While rarely life-threatening, AF is almost universally associated with increased morbidity and mortality, predominantly through an increased risk of thromboembolic events, left ventricular dysfunction, as well as significant impairments in functional capacity and health-related quality of life (HRQOL).[1-8] Improvement in HRQOL, with a secondary reduction of disability and health-care resource utilization, is one of the major therapeutic goals in the management of AF.
Keywords: Ablation/ICD/Surgery; Arrhythmias; Clinical Electrophysiology; Drugs; Electrophysiology.